Evolus (EOLS) Price & Analysis

Compare

559 Followers

EOLS Stock Chart & Stats

$6.79

-$0.47(-4.38%)

At close: Jan 08 4:00 PM EST

$6.79

-$0.47(-4.38%)

Day’s Range― - ―

52-Week Range$5.71 - $17.44

Previous CloseN/A

Volume344.54K

Average Volume (3M)988.66K

Market Cap

$439.21M

Enterprise Value$687.57M

Total Cash (Recent Filing)$61.74M

Total Debt (Recent Filing)$154.91M

Price to Earnings (P/E)―

Beta0.91

Next Earnings

Nov 05, 2025

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding64,685,420

10 Day Avg. Volume752,657

30 Day Avg. Volume988,659

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.57

Enterprise Value/Revenue2.48

Enterprise Value/Gross Profit3.71

Enterprise Value/Ebitda-18.82

Forecast

1Y Price Target

$19.25

Price Target Upside183.51% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

LeadershipEvolus announced that Tatjana Mitchell was appointed Chief Financial Officer, effective today. This is a strong hire given similarities across the two consumer-focused businesses.

New Product IntroductionThe introduction of Evolysse fillers provides growth drivers for the company in addition to Jeuveau.

Product EffectivenessJeuveau has superior effectiveness as shown in an independent study, which could help increase market share once demand returns.

Bears Say

Consumer SentimentContinued tariff threats and negative macroeconomic factors are expected to weigh on consumer sentiment and aesthetics demand.

Market ConditionsNear-term market softness is likely to continue impacting Jeuveau's sales.

Revenue UncertaintyManagement's 2028 revenue 'target' of $700M is an overhang, creating uncertainty among investors.

Evolus News

Needham medtech & diagnostics analysts hold analyst/industry conference call

MedTech & Diagnostics Analysts Matson & Belanger, along with plastic surgeon Dr. Ross Stutman, plastic surgery and aesthetics...

18d ago

ABBV

APYX

Evolus’s Potential Amid Market Challenges: Buy Rating Supported by Undervaluation and Growth Prospects

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Evolus. The associated price target remains...

3d ago

EOLS

Strategic Leadership and Stability Drive Buy Rating for Evolus

BTIG analyst Sam Eiber has reiterated their bullish stance on EOLS stock, giving a Buy rating on August...

2M ago

EOLS

Evolus Appoints Tatjana Mitchell as New CFO

The latest announcement is out from Evolus ( ($EOLS) ). On September 8, 2025, Evolus, Inc. announced the...

2M ago

EOLS

Evolus appoints Tatjana Mitchell as CFO

Evolus (EOLS) announced the appointment of Tatjana Mitchell as its CFO, effective September 8. Mitchell has over 20...

2M ago

EOLS

Evolus announces Evolysse Sculpt trial meets primary endpoint

Evolus (EOLS) announced topline results from a U.S. pivotal study of Evolysse Sculpt, an injectable hyaluronic acid gel...

2M ago

EOLS

Evolus submits Evolysse premarket approval application to FDA

Evolus (EOLS) announced that it has submitted the final module of its premarket approval application to the FDA...

2M ago

EOLS

Evolus, Inc. Advances Safety Study of NUCEIVA for Glabellar Lines

Evolus, Inc. (($EOLS)) announced an update on their ongoing clinical study. Evolus, Inc. is conducting a non-interventional post-authorization...

3M ago

EOLS

Evolus, Inc. Faces Financial Instability Amid Economic Uncertainty and Consumer Spending Risks

Evolus, Inc. (EOLS) has disclosed a new risk, in the Demand category. Evolus, Inc. faces significant business risks...

3M ago

EOLS

Evolus, Inc. Earnings Call: Mixed Sentiments and Strategic Goals

Evolus, Inc. (($EOLS)) has held its Q2 earnings call. Read on for the main highlights of the call....

3M ago

EOLS

Evolus: Strategic Growth and Cost Optimization Support Buy Rating Amid Market Challenges

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Evolus, with a...

3M ago

EOLS

Disney reports Q3 beat and NFL deal, Uber authorizes $20B buyback: Morning Buzz

The major averages were higher near noon, led by the Nasdaq, as investors reacted to another heavy dose...

3M ago

Evolus price target lowered to $18 from $21 at BTIG

BTIG analyst Sam Eiber lowered the firm’s price target on Evolus (EOLS) to $18 from $21 and keeps...

3M ago

EOLS

Evolus cut to Hold at Needham after ‘significant’ Jeuveau downturn

Needham downgraded Evolus (EOLS) to Hold from Buy and removed the firm’s prior $22 price target The company’s...

3M ago

EOLS

EOLS FAQ

What was Evolus Inc’s price range in the past 12 months?

Evolus Inc lowest stock price was $5.71 and its highest was $17.44 in the past 12 months.

What is Evolus Inc’s market cap?

Evolus Inc’s market cap is $439.21M.

When is Evolus Inc’s upcoming earnings report date?

Evolus Inc’s upcoming earnings report date is Nov 05, 2025 which is in 9 days.

How were Evolus Inc’s earnings last quarter?

Evolus Inc released its earnings results on Aug 05, 2025. The company reported -$0.247 earnings per share for the quarter, missing the consensus estimate of -$0.099 by -$0.148.

Is Evolus Inc overvalued?

According to Wall Street analysts Evolus Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Evolus Inc pay dividends?

Evolus Inc does not currently pay dividends.

What is Evolus Inc’s EPS estimate?

Evolus Inc’s EPS estimate is -0.16.

How many shares outstanding does Evolus Inc have?

Evolus Inc has 64,685,420 shares outstanding.

What happened to Evolus Inc’s price movement after its last earnings report?

Evolus Inc reported an EPS of -$0.247 in its last earnings report, missing expectations of -$0.099. Following the earnings report the stock price went down -28.507%.

Which hedge fund is a major shareholder of Evolus Inc?

Currently, no hedge funds are holding shares in EOLS

Evolus Stock Smart Score

Underperform

Fundamentals

Return on Equity

-9999.00%

Trailing 12-Months

Asset Growth

-2.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Evolus Inc

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus (EOLS) Earnings & Revenues

Historic Earnings Reports

EOLS Company Deck

EOLS Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call depicted both strong achievements, particularly with the successful launch of Evolysse and international expansion, and significant challenges, including decreased demand for Jeuveau and a challenging market environment. While there are optimistic signs for the future, such as expected improvements in demand and strategic cost optimizations, the immediate outlook is hindered by current market conditions.View all EOLS earnings summaries

EOLS Stock 12 Month Forecast

Average Price Target

$19.25

▲(183.51% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","9":"$9","13":"$13","17":"$17","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9,13,17,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.15,7.2153846153846155,8.28076923076923,9.346153846153847,10.411538461538463,11.476923076923077,12.542307692307693,13.607692307692307,14.673076923076923,15.73846153846154,16.803846153846152,17.869230769230768,18.934615384615384,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.15,7.157692307692308,8.165384615384616,9.173076923076923,10.180769230769231,11.188461538461539,12.196153846153846,13.203846153846154,14.211538461538462,15.21923076923077,16.22692307692308,17.234615384615385,18.24230769230769,{"y":19.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.15,7.061538461538462,7.973076923076923,8.884615384615385,9.796153846153846,10.707692307692309,11.61923076923077,12.53076923076923,13.442307692307693,14.353846153846154,15.265384615384615,16.176923076923075,17.088461538461537,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >